BioCentury

7:00 AM GMT, Jul 21, 2008
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Leveraging ViroPharma

Lev Pharmaceuticals Inc. might not seem like an obvious choice to be acquired by ViroPharma Inc., which has been focused on infectious diseases and transplant medicine. ViroPharma, however, says it's a clear fit with its strategy of building franchises within narrowly focused specialized hospital markets.

ViroPharma will acquire Lev for $442.9 million ($355.6 million in cash and $87.3 million in stock) and

Read the full 612 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.